AFP and hepatocellular carcinoma: More importantly, 70.8% (85 of 120) of early HCC with negative AFP in the Testing Cohort and 67.7% (44 of 65) of AFP-negative early HCC in the Validation Cohort could be diagnosed by Egfl7 (Table 8).